Abstract
Previous report of the randomized trial has demonstratedthat the novelpoly-L-lactic acidNeoVas (Lepu Medical, Beijing, China)bioresorbable scaffolds (BRS) was non-inferior to cobalt-chromium everolimus-eluting stents (CoCr-EES)for 1-year target lesion failure in patients with noncomplex coronary
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
